Aeolus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of fibrotic and inflammatory diseases. The company’s research and development efforts are centered on small-molecule and biologic candidates designed to modulate key pathways involved in tissue scarring and immune response. Aeolus aims to address unmet medical needs in conditions such as idiopathic pulmonary fibrosis, liver fibrosis and acute lung injury by advancing compounds from discovery through clinical trials.
The company’s lead programs include several preclinical and early clinical candidates targeting fibrosis and inflammation. One of its flagship assets is AEL-101, an oral small molecule inhibitor of the transforming growth factor-beta (TGF-β) signaling pathway, which plays a critical role in fibroblast activation and extracellular matrix deposition. In addition, Aeolus is advancing AEL-201, a monoclonal antibody aimed at neutralizing pro-inflammatory cytokines implicated in acute respiratory distress syndrome. These programs underscore Aeolus’s approach of combining molecular biology insights with rigorous translational research to create differentiated therapies.
Aeolus Pharmaceuticals was founded in 2015 and is headquartered in Irvine, California, with additional research operations in Boston, Massachusetts. The company’s scientific teams engage in collaborative partnerships with academic institutions and contract research organizations across North America and Europe to support preclinical studies and clinical trial execution. By leveraging these alliances, Aeolus ensures access to state-of-the-art technologies and patient populations needed to validate its therapeutic platforms.
Leadership at Aeolus is led by Chief Executive Officer Gary Strumwasser, who brings over two decades of experience in pharmaceutical development and biotechnology commercialization. He is supported by a seasoned management team with backgrounds in clinical operations, regulatory affairs and medicinal chemistry. Guided by a mission to improve outcomes for patients living with debilitating fibrotic diseases, the company continues to expand its pipeline and pursue strategic collaborations to accelerate the delivery of new treatments to market.
AI Generated. May Contain Errors.
Free AOLS Stock Alerts